CAMBRIDGE, Mass. — InduPro Inc. has appointed Amanda J. Redig, MD, PhD, as chief medical officer as the biotechnology company advances its lead program toward Phase 1 studies.
InduPro, which is based in Seattle and Cambridge, Mass., is developing therapeutics for cancer and autoimmune diseases by defining spatial relationships among membrane proteins. The company said Redig will lead its development strategy as it moves its emerging clinical pipeline forward.
Redig is a medical oncologist, oncology drug developer and life sciences executive with experience in academic medicine, pharmaceutical and biotechnology drug development, and life sciences investing.
She previously served as senior vice president and head of clinical development at HotSpot Therapeutics, where she led Phase 1 clinical development for the company’s first-in-human immuno-oncology program. Before that, she was a principal and member of the investment team at Blackstone Life Sciences, where she supported life sciences investments, including multiple oncology transactions.
Redig also served as executive medical director and head of translational science, oncology, at Takeda Pharmaceuticals. In that role, she helped build and lead a translational sciences organization supporting an oncology pipeline of more than 40 assets from preclinical discovery through clinical development and post-approval life cycle management.
“Dr. Redig brings a unique blend of scientific rigor, clinical and translational leadership, industry insight, and patient-centered experience to InduPro as we build our emerging clinical pipeline,” said Prakash Raman, PhD, chief executive officer of InduPro. “Her work across the entire life sciences ecosystem will provide invaluable insights as we advance potential first-in-class oncology treatments for patients, beginning with IDP-001, a proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel tumor-associated antigen.”
Redig previously served on the faculty at Dana-Farber Cancer Institute and Harvard Medical School as a thoracic oncologist and inpatient oncology hospitalist. She began her career at Dana-Farber as a thoracic oncologist and translational investigator, where she participated in clinical trial enrollment and helped develop investigator-sponsored studies.
She served as principal investigator or sub-investigator across a thoracic oncology clinical trial portfolio that included early studies of PD-1/PD-L1 inhibitors and targeted therapies. She also worked on early osimertinib clinical and translational development.
“I am thrilled to join InduPro at such an important stage in the company’s growth, as we prepare to initiate a Phase 1 study for the first asset from InduPro’s proximity-guided platform to enter clinical development,” said Redig. “Throughout my career across academic medicine and industry, I have been focused on translating compelling science into meaningful therapies for patients, and I believe InduPro’s differentiated approach to mapping cell-surface protein neighborhoods can open an entirely new path for precision cancer medicines. I look forward to working with and growing our exceptional team to advance our pipeline programs targeting critical areas of unmet need.”
Redig earned her MD and PhD in cancer biology from Northwestern University Feinberg School of Medicine. She completed her internal medicine residency at Brigham and Women’s Hospital and her fellowship in medical oncology through the Dana-Farber/Partners Cancer Care fellowship program.
She received her bachelor’s degree in biochemistry from the University of Arizona and is an author on more than 40 peer-reviewed publications.
